UCL Campaign


UCL celebrates 10 years of awe-inspiring research at the UCL Cancer Institute

11 October 2018

UCL Cancer Institute turns 10 and is celebrated for its pursuit of kinder, more effective therapies for cancer patients.

Mark Emberton at the UCL Cancer Institute 10 Year Anniversary

On October 10, UCL and guests came together at the Royal Society to celebrate a decade since the UCL Cancer Institute opened. 

Guests joined UCL President and Provost, Professor Michael Arthur, UCL Cancer Institute Director Professor Tariq Enver and other Institute researchers for an evening that showcased a snapshot of the very latest developments in cancer research.  
An early decision to focus on biotherapies as the future of cancer treatment has driven enormous successes in the progression of biotherapies at the Institute. 

When combined with traditional therapies, the new class of treatments – including immune cell therapy, immune checkpoint inhibitors, antibodies and therapeutic vaccines – now provide some of the most targeted and precise treatment options we have ever seen. 

Treatments that – in the next ten years – will be more effective and less toxic, and will result in more patients living longer with better quality of life.

“We have an ambition to transform the way we think about cancer over the next 10 years,” said Professor Tariq Enver during his welcome address. 

Delving further into the next decade of cancer research, guests also took part in a panel discussion led by Professor Mark Emberton, Dean of Medical Sciences at UCL. 

Panellists included:

  • Professor Charlie Swanton - Chair in Personalised Medicine at UCL Cancer Institute
  • Dr Claire Roddie - Associate Professor at UCL and Consultant Haematologist at UCLH
  • Dr Joana Neves - Clinical Research Associate a UCL Department of Nanotechnology
  • Dr Simon Walker-Samuel - Senior Research Fellow at UCL Centre for Advanced Biomedical Imaging

More than the sum of its parts

To achieve more precise and effective treatments, the Institute has harnessed expertise across UCL’s faculties such as engineering, computer science, maths and physics. 

The UCL Cancer Institute also plays a critical role in the unique coalition of world-renowned organisations that form a greater London Cancer Campus, including University College London Hospitals (UCLH), Great Ormond Street Hospital (GOSH), the Francis Crick Institute and more.

These collaborative partnerships place UCL in a strong position to make major contributions to the UK’s cancer patients and to the worldwide community.

Founded on philanthropy 

The UCL Cancer Institute itself is built on philanthropy.

Just over 10 years ago Children with Cancer UK helped establish the Paul O’Gorman building which houses the Institute. Children with Cancer UK was set up by Eddie and Marion O’Gorman in memory of their son Paul who died of leukaemia aged 14 and their daughter Jean who passed away from cancer nine months later. 

Alongside a number of other charitable partners, Children with Cancer UK continue to fund research into childhood leukaemia and acute myeloid leukaemia at UCL.

Cancer is a priority project for UCL’s It’s All Academic fundraising campaign. UCL’s ideas and discoveries are shaping the future, improving lives and having a massive impact on London and the wider world. The Campaign is UCL’s biggest ever philanthropic endeavour, aiming to raise £600 million for world-impacting research. 

More information:
UCL Cancer Institute
It’s All Academic Campaign